DelveInsights, “Insight into the liver cancer pipeline, 2022,” the report provides in-depth insights into 75+ companies and 75+ pipeline drugs in the liver cancer pipeline landscape. It covers the pipeline drug profiles, including both clinical and non-clinical stage products. It also includes therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.
Key Findings from the Liver Cancer Pipeline Report
- DelveInsight Liver Cancer Pipeline Report shows a robust space with 75+ active players working to develop 75+ pipeline therapies for liver cancer.
- The leading liver cancer companies such as Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group and others are evaluating novel drugs for liver cancer to improve the treatment landscape.
- Promising pipeline therapies for liver cancer at various stages of development include Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab , LioCyx-M, DKN-01, SD-101, BO-112,…
